Emergent BioSolutions EBS
NYSE EBS
$6.04 -0.06 (-0.98%)
At close: Nov 10, 2026 · 4:00 PM EST

Emergent BioSolutions (EBS) Goodwill impairment charges (2022 - 2026)

Updated

Emergent BioSolutions' Goodwill impairment charges came in at $218.2 million for FY2023, compared with $6.7 million in FY2022.

Analysis

Emergent BioSolutions (EBS) Goodwill impairment charges (2022 - 2026) Analysis & Trends

  • Per Business Quant, earlier years put Goodwill impairment charges at $6.7 million in FY2022 (-83.9%) and $41.7 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Emergent BioSolutions 309.85 Mn -371.25 Mn 29.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 191.30 Mn
Jun 30, 2024 27.20 Mn
Dec 31, 2023 -306.70 Mn
Sep 30, 2023 218.20 Mn
Jun 30, 2023 306.70 Mn
Dec 31, 2022 6.70 Mn
API Access

Emergent BioSolutions Goodwill impairment charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=goodwill-impairment-charges&ticker=EBS&period=max&api_key=YOUR_API_KEY